New Jersey Trim Clinic vs Found Health: NJ Comparison
Published by New Jersey Trim Clinic · Updated 2025-12-12
Quick Take
Found is a national tele-prescriber that mixes GLP-1s with older off-label weight loss medications. New Jersey Trim Clinic is GLP-1-focused, NJ-physician-led, and one flat $149/month.
👉 Check If You Qualify in 2 Minutes
What's Different
- Prescriber model: Found assigns from a national pool; we keep one NJ-licensed physician with you.
- Medication mix: Found may suggest phentermine, bupropion, or metformin alongside GLP-1; we focus on GLP-1 done well.
- Pricing: Found's bundle pricing varies by medication; ours is one number — $149/month.
Food Noise
The single biggest predictor of long-term success is whether the program treats food noise. We build the entire intake around it.
👉 Book a Free Consultation · See $149/mo Pricing
MEDICAL SOURCES & FURTHER READING
Read the source alongside the specific topic it supports. These independent sources do not endorse New Jersey Trim Clinic. Research findings are not a prediction of your results.
- NIH/NIDDK — Prescription Medications to Treat Overweight & Obesity
Supports: Weight-management medication requires individualized prescribing; eligibility, benefits, risks and ongoing treatment should be discussed with a healthcare professional. Nutrition and physical activity remain part of treatment.
- Mayo Clinic — Prescription weight-loss drugs
Supports: Prescription weight-loss medicines have eligibility restrictions, potential side effects and a need for professional oversight; they are used alongside lifestyle measures.
- Cleveland Clinic — GLP-1 Agonists
Supports: GLP-1 receptor agonists act on appetite and satiety, help regulate blood glucose and can slow stomach emptying. Common adverse effects include nausea, vomiting and diarrhea.
Evidence limits: The extent and duration of effects differ by drug, dose and individual; a general mechanism does not establish a guaranteed response.
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Supports: A randomized study reported reduced hunger, food cravings and energy intake, and improved control of eating with semaglutide.
Evidence limits: This study does not establish a diagnosis of 'food noise', prove that all intrusive food thoughts have one cause, or show that every patient will experience relief. It found no evidence of delayed gastric emptying at week 20 using its indirect test.
- FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Supports: Compounded GLP-1 drugs are not FDA-approved. FDA describes dosing, quality, storage and other safety concerns, and advises that compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug.
Evidence limits: Pharmacy registration is not FDA approval of a compounded product. Clinical trials of approved drugs do not establish the safety or effectiveness of compounded formulations.
RESEARCH & REFERENCES
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. Diabetes, Obesity and Metabolism. 2021.
Research published in Diabetes, Obesity and Metabolism reported improvements in appetite and control of eating in a 20-week trial of semaglutide in adults with obesity.
General education is not individualized medical advice. Prescription treatment requires evaluation by a licensed provider. Eligibility, medication and dosing depend on individual circumstances.
Compounded drugs are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before marketing. Compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug. Published studies of approved medications do not establish equivalent safety or effectiveness of compounded products.